A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria.
Measuring tumor response to chemotherapy is important for both clinical decision-making and for multi-institutional studies. Thymoma tends to spread along the pleura: a challenge for accurate tumor measurement. Inaccurate and inconsistent tumor measurements often compromise results from clinical trials that are dependent on identifying response rate and progression-free survival. In this article, we sought to provide a practical guide on how to measure thymoma by the International Thymic Malignancy Interest Group's recommendations for standard outcome measures. The aim of this article is to clarify this measuring technique, lead to consistency between institutions, and minimize intra- and interobserver variability.
*Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas; †The Daniel and Gloria Blumenthal Cancer Center, Paramus, New Jersey, and the Division of Thoracic Surgery, The Valley Hospital, Ridgewood, New Jersey; ‡Thoracic and Gastrointestinal Oncology Branch, National Cancer Institute, Bethesda, Maryland; and §Department of Surgery, Division of Thoracic Surgery, Yale University School of Medicine, New Haven, Connecticut.
Marcelo F
MF
Benveniste
Robert J
RJ
Korst
Arun
A
Rajan
Frank C
FC
Detterbeck
Edith M
EM
Marom
D006801:Humans; D009375:Neoplasms, Glandular and Epithelial / Q000000981:diagnostic imaging* / Q000628:therapy*; D011859:Radiography; D066066:Response Evaluation Criteria in Solid Tumors; D013953:Thymus Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*